Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
